Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Xcel Energy Inc (XEL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Xcel Energy Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.84 (market cap $4.49B), while Xcel Energy Inc trades at $80.05 (market cap $50.36B). The key difference: Xcel Energy Inc is far larger — about 11.2× ACADIA Pharmaceuticals Inc.'s market cap, and Xcel Energy Inc pays a 2.94% dividend while ACADIA Pharmaceuticals Inc. pays none. Which is the better fit depends on your goals.
| ACAD | XEL | |
|---|---|---|
Market Cap | $4.49B | $50.36B |
Sector | Health | Utilities |
52-Week High | $28.06 | $83.91 |
52-Week Low | $20.06 | $67.56 |
Enterprise Value | $3.69B | $87.80B |
Dividend Yield | — | 2.94% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
Xcel Energy (XEL) trades at $80.67, down 1.57% on the day, with a bullish technical signal and strong analyst support (17 buy ratings). The stock shows steady revenue growth, with 2025 revenue at $14.67 billion and net income of $2.02 billion, though recent quarters saw mixed earnings results. A $60 billion capital expenditure plan through 2030 aims to capitalize on rising electricity demand from data centers and electrification trends.
The outlook is positive, supported by a consensus price target of $91.50, implying 13% upside. Key risks include regulatory pushback on rate hikes and high debt levels, with debt-to-assets at 41.64% in 2025. The dividend yield of 2.87% adds income appeal, but investors should monitor execution of the expansive capex plan and regulatory approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Xcel Energy Inc
Xcel Energy manages utilities serving 3.7 million electric customers and 2.1 million natural gas customers in eight states. Its utilities are Northern States Power, which serves customers in Minnesota, North Dakota, South Dakota, Wisconsin, and Michigan
Read more on XEL →
